Drug Profile
Research programme: inflammatory disease therapeutics - Ore Pharmaceuticals
Alternative Names: ORE 10002Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Lundbeck A/S
- Developer Ore Pharmaceuticals
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation